Clinical trial · Interventional
An Extension Study of LON002 in Patients With Cancer
NCT02390986CI-TRIAL-00017160unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this clinical trial is to evaluate the long term safety and efficacy of LON002.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumours | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LON002 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Proportion of patients with Adverse Events grade ≥3 related to LON002 and Serious Adverse Events related to LON002 as a measure of safety and tolerability.
- timeFrame
- Participants will be followed for the duration of their study treatment, an expected average of 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Written informed consent; 2. Has completed a LondonPharma sponsored parent trial of LON002 and continues to have clinical benefit in the judgement of the investigator; 3. Eligible for continuation of LON002 treatment at the end of the parent trial, according to the parent trial protocol; 4. Able to comply with the protocol LON002-003; 5. Women of child bearing potential must have a negative pregnancy test before the start of treatment; 6. Sexually active women of childbearing potential must be using an acceptable form of contraception for the duration of dosing and for 30 days thereafter; 7. Male subjects with female partners of childbearing potential should use condoms for the duration of dosing and for 30 days thereafter Exclusion Criteria: 1. Has not completed a LondonPharma sponsored parent trial of LON002; 2. Unequivocal evidence of disease progression; 3. Unacceptable toxicity experienced in the parent trial;
References
Publications (0)
Data not yet available
No reference posted for this study.